Radiographic damage and 6-month progression in placebo groups of 3 biologics trials. Values are mean (SD) unless specified otherwise.
| Variables | ATTRACT | ASPIRE | LITHE | |||
|---|---|---|---|---|---|---|
| Baseline damage†, mean (SD)/mean (range) | 82.0 (77.0) | 11.3 (15.9) | 28.5 (0–190.5) | |||
| Progression | ||||||
| 1 yr, trial report | 7.0 (10.3) | 3.7 (9.6) | 1.1‡ | |||
| 6 mos, interpolated | 3.5 (6.2) | 1.8 (4.8) | 0.6 | |||
| 6 mos, current dataset | 4.8 (9.1) | 2.4 (7.4) | 0.5 (1.3) | |||
| Glucocorticoid use | − | + | − | + | − | + |
| Baseline damage | 92.5 (80.6) | 80.6 (80.9) | 11.6 (15.7) | 10.3 (16.3) | 25.3 (29.0) | 31.0 (33.9) |
| Progression | 7.7 (13.1) | 2.9 (4.9) | 3.2 (7.9) | 0.9 (6.4) | 0.5 (1.4) | 0.5 (1.3) |
↵† ATTRACT and ASPIRE expressed in Sharp/van der Heijde points (range 0–440); LITHE expressed in Sharp-Genant points (range 0–290).
↵‡ SD not reported. ATTRACT: Anti-Tumor necrosis factor Trial in Rheumatoid Arthritis with Concomitant Therapy; ASPIRE: Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset; LITHE: Tocilizumab Safety and the Prevention of Structural Joint Damage.